Document Detail


The pharmacological basis for the combination of calcium channel antagonists and angiotensin converting enzyme inhibitors in the treatment of hypertension.
MedLine Citation:
PMID:  8576784     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
IMPROVING THE TREATMENT OF HYPERTENSION: The results of basic and clinical research in hypertension over the last 30 years have shown that this disease cannot be treated merely by inducing vasodilation and a fall in blood pressure. The development of high blood pressure is associated with changes in carbohydrate and lipid metabolism and with the development of organ damage, mainly of the heart and kidneys. It is now clear that different elements of blood pressure control mechanisms can lead to hypertension, emphasizing the need to select the appropriate type of hypertensive drug in treating different patients. COMBINATION OF CALCIUM CHANNEL ANTAGONISTS AND ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS: Calcium channel antagonists and ACE inhibitors have synergistic effects on sodium and fluid balance and on the renin-angiotensin-aldosterone system. Thus a combination of these two antihypertensive drug classes is likely to be beneficial in certain subgroups of patients with hypertension. Large clinical trials are needed to determine whether this is indeed the case.
Authors:
H Osswald; B Mühlbauer
Related Documents :
9876364 - A systematic review of the use of computers in the management of hypertension.
10578214 - Simple blood pressure guidelines for primary health care.
20508624 - Effects of blood pressure control with perindopril/indapamide on the microcirculation i...
20978214 - Spironolactone management of resistant hypertension.
1598964 - The effect of intracameral ethacrynic acid on the intraocular pressure of living monkeys.
16275194 - Effect of sildenafil on cardiac performance in patients with heart failure.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of hypertension. Supplement : official journal of the International Society of Hypertension     Volume:  13     ISSN:  0952-1178     ISO Abbreviation:  J Hypertens Suppl     Publication Date:  1995 Aug 
Date Detail:
Created Date:  1996-03-13     Completed Date:  1996-03-13     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  8501422     Medline TA:  J Hypertens Suppl     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  S21-8     Citation Subset:  IM    
Affiliation:
Department of Pharmacology, Medical Faculty, University of Tübingen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / administration & dosage*,  adverse effects
Antihypertensive Agents / administration & dosage*,  adverse effects
Blood Pressure / drug effects,  physiology
Calcium Channel Blockers / administration & dosage*,  adverse effects
Coronary Disease / physiopathology,  prevention & control
Drug Therapy, Combination
Humans
Hypertension / drug therapy*,  physiopathology
Risk Factors
Vasodilation / drug effects,  physiology
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Calcium Channel Blockers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Main objectives and new aspects of combination treatment of hypertension.
Next Document:  The heart and vascular changes in hypertension.